Home
overview

Impending patent expirations on blockbuster biologics and a volatile financial environment is causing payers to seek wider adoption of biosimilars in order to manage growing healthcare costs. As a result, the biosimilars manufacturing market is set to expand over the next decade and beyond as the drive to find cost-effective alternatives to biologics leads to the growing. In fact analysts predict that between 2013-2018, the global biosimilars market will grow at 27.58 %.

Returning for its fitfth year and following on from the major success of previous events, SMI are proud to present the 5th annual Biosimilars & Biobetters Conference, 29th-30th September, 2014, London. With an in-depth focus on the current and future landscape of the biosimilars market, this meeting will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Join us and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

Key topics include:

• Biosimilars, biobetters - the patients perspective
• The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry
• What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry
• Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars
 
• And much more!

Previous testimonial:
“A thoroughly interesting and very informative conference with excellent chairs and presenters. More of the same please - Abbott

Dear Visitor, HEREyou can download:

- List of attendees – 2014
- List of past attendees (2011-2013)

This two day networking event will invite in depth discussion of the key drivers impacting Biosimilars and Biobetters development both home and abroad. Join us and discover what is going in this burgeoning market to:

 • Hear cutting edge presentations and key case   studies form leading pharma and biotech experts.
Network and learn from your peers.
• Discover what is happening in the market now and in the future.

Senior Vice Presidents, Vice Presidents, Directors, Heads of Department with responsibility in the following departments:-

Intellectual Property
Legislation and Policy Advisers
Analysts
Business Development
Biostatistician
Licensing
Manufacturing
Bioequivalence
Drug and Safety Assessment
Market Strategy
Regulatory/Legal Affairs
Biomedical Product Development
Health Economics
Scientific Affairs
Research and Development
 

Abbvie Ltd; Antitope; Arnold and Porter; Boehringer Ingelheim Pharma AG; Boehringer Ingelheim Pharma GmbH & Co. KG; Bristows; Daiichi Sankyo Development Ltd.; Dr Reddy's Laboratories; Elsadek Consulting; Fresenius Kabi Deutschland GmbH; Glycotope GmbH; Harvest Moon Pharmaceuticals; Hospira France; IMS Consulting; Interpharm Consultancy; J A Kemp & Co; Janssen Pharmaceutica; Lilly Research Centre Ltd; Medis D O O; Merck; Norwegian Medicines Agency; Novartis Horsham Research; Novo Nordisk Region International Operations A/S; Oranyei BV; Parexel; Parexel International; Pfizer; PRA International; pSivida; Quintiles; Quintiles Ltd; Regeneron Pharmaceuitcals Inc; Roche AG; Roche Norway; S N B L Usa Ltd; SAI MedPartners; Sankio Pharma Gmbh; Sanofi-Aventis; Swedish Orpan Biovitrum; Univercelles S.A.; University Of Limerick; Vision Healthcare Consultancy Ltd; Voisin Consulting Life Sciences;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

9:10 What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry

Alan Sheppard

Alan Sheppard, Global Head Generics, Thought Leadership, IMS Health

• Reviewing the sustainability of the biosimilars market, will it be saturated in the future?
• The big question…who will be most successful, those who are:
o the fastest to market
o generates the most similar biosimilar
• Evaluating the barriers to market entry and uptake for biosimilars
• Where are we heading and what needs to happen

9:50 The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

• Understanding how this will shape the competitive, dynamic and commercially lucrative biosimilars market segment
• Reviewing why big pharma companies are considering entering with market with monoclonal antibody biosimilars
• Will their experience in marketing, manufacturing skills and industry knowledge give them a competitive advantage over those already in the market
• What are their weaknesses?

10:30 Morning Coffee

10:50 A clinical perspective on biosimilars: development and beyond

Uwe Gudat

Uwe Gudat, Head of Safety Biosimilars, Merck Switzerland Limited

• The challenge - creating strategies to overcome the obstacles we face
• The means - utilizing the tools at our disposal
• The scenarios - a collection of possible outcomes
 

11:30 Biosimilars/ Biobetters in the USA

• US PTO regulations extending the impact of the Myriad decision
• Strategy and hurdles for patenting your biosimilar in the US
• Update on evolving FDA regulations for biosimilars: why are there no approvals in the US?

Albin (Jim) Nelson

Albin (Jim) Nelson, Partner, Schwegman, Lundberg, Woessner IP, P.A.

Robin Chadwick

Robin Chadwick, Partner, Schwegman, Lundberg, Woessner IP

12:10 Networking Lunch

13:10 Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars

• Taking an in-depth look at the discussion regarding the WHOs initiative for a unique identifier for biologics – what will this mean?
• The use of identical INNs for biosimilars could lead to inadvertent switching at the pharmacy - true or false?
• What is the view at home and abroad?
• USA - GphA and originator citizen petitions to the FDA

Peter Wittner

Peter Wittner, Senior Consultant, Interpharm Consultancy

13:50 You can’t injunct me – I’m a biosimilar!

Dominic Adair

Dominic Adair, Partner, Bristows

• Review of the principles governing interim injunctions in patent litigation
• Application of those principles to pharma cases
• Why biosimilar cases may not necessarily be a good fit – will the injunctions stick?
 

14:30 European update - the latest in regulatory thinking

• Understanding current regulatory legislation and guidelines for biosimilars in Europe, reviewing the regulatory pathways in other jurisdictions •
• What are the regulatory requirements for non-clinical and clinical studies in developing biosimilars  
• Other aspects of the regulatory framework to consider when preparing a marketing authorisation application

 

 

 

Sarah Faircliffe

Sarah Faircliffe, Legal Director , Bird & Bird

Liz Fuller

Liz Fuller, Partner, Bird & Bird

15:10 Afternoon Tea

15:30 The case for biosimilars–a payer’s perspective

Erik A. Stene

Erik A. Stene, Senior Advisor/MPhil Econ, Department for pharmacoeconomics/reimbursement/value assessment, Norwegian Medicines Agency

•         Why are payers interested in utilizing biosimilars?
•         Switching or not switching in pharmacies?
•         Switching or not switching for economical reasons after treatment initiation/during treatment?
•         What will happen in Norway onwards?

16:10 Same, similar, equivalent, this is a serious game! Proving that a biosimilar is ‘similar’ to the originator is not trivial pursuit!

Michael Tovey

Michael Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan

• Defining biosimilarity
• How similar is the biosimilar to the innovator…measuring how much work this entails  at the early stage
• Evaluating what metrics and analytical similarity assessments should be employed when designing a biosimilar development program
• Determining type and volume of clinical data required for establishing biosimilarity
• Establishing validated standardized assays that allow direct comparisons of the relative potency and immunogenicity of the biosimilar and the innovator product
• Considering the limitations of conventional biological assays that may be inadequate to detect differences resulting from a change in the manufacturing process
• Conducting a non-clinical or a clinical study

16:50 Pre-Launch supply readiness for biosimilars

Samuel Woodley

Samuel Woodley, U.S. Senior Patent Attorney, Biosimlars Business, Boehringer Ingelheim Pharma GmbH & Co. KG

• Understanding the “safe harbor” provisions against patent infringement in the United States
• The Board exemption to patent infringement, across the European Union and in individual countries
• Maximizing benefit of the exemptions to minimize risks of infringement before launch

17:30 Chairman’s Closing Remarks and Close of Day One

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

9:10 Biosimilars - hurdles to patients' access

Michel  Mikhail

Michel Mikhail, Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi

• Development of biosimilars: A case study
• Patent protection
• INN issue
• Switching: interchangeability and substitution

9:50 What do they really think...Reviewing customer perceptions of biosimilars in Europe

Ineke Braat

Ineke Braat, CEO, PanGenerika

• Discussing what do doctors think of biosimilars and how willing are they to prescribe them
• Monitoring how patients react when their doctor prescribes a biosimilar?
• Are payors pushing for more utilization of biosimilars in Europe
 

10:30 Morning Coffee

10:50 Innovations in creating best in class biosuperior biologics: meeting the challenges of biosimilars

Rakesh Dixit

Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune (AstraZeneca Biologics)

11:30 Pharmacovigilance considerations for biologics and biosimilars

Catherine Akers

Catherine Akers, Regulatory Affairs Manager, Amgen Inc

• Unique characteristics for biologics which influence their safety profile
• Importance for accurate traceability to allow effective pharmacovigilance
• How biologics have been recognised in the new EU pharmacovigilance legislation and what implementation looks like across Europe.


 

12:10 Networking Lunch

13:10 Tracking the introduction of biosimilar infliximab in Norway

Steinar Madsen

Steinar Madsen, Medical Director, Norwegian Medicines Agency

• What are the attitudes of physicians?
• Switching study – what is the status?  
• Monitoring prices and sales
 

13:50 Designing and executing comparability studies…an important ‘key’ in the development of products

Alok Sharma

Alok Sharma, Principal Scientist & Head Analytical Development , Lupin Laboratories Ltd

14:30 Afternoon Tea

14:50 Biosimilars, biobetters - the patients perspective

Victoria Fine

Victoria Fine, Managing Director , Psoriansense

• A patients understanding of biologics, biobetters & biosimilars
• What biosimilars & biobetters actually mean to patients
• The true impact of biosimilars and biobetters
 

15:30 A new dawn… biosimilar monoclonal antibodies (mAbs), a new milestone for the biosimilar market!

Carsten Brockmeyer

Carsten Brockmeyer, CEO, Formycon AG

• Reviewing how approval of the first biosimilar monoclonal antibody therapy will impact the industry, what are the implications for 2014 and beyond
• Evaluating if this will spearhead the start of a new era of mAbs in the pharma industry
• Discussing how to get regulatory approval for your mAb
• Will this bring greater commercial rewards
• Will generic companies continue to dominate, or can Big Pharma gain control with its huge marketing muscle?

 

16:10 Market dynamics in biosimilars

Ranjith  Gopinathan

Ranjith Gopinathan, Program Manager - Life Sciences, Healthcare Practice Europe, Frost & Sullivan

16:50 Chairman’s Closing Remarks and Close of Day Two

Richard Dicicco

Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

+

FEATURED SPEAKERS

Michel  Mikhail

Michel Mikhail

Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi
Peter Wittner

Peter Wittner

Senior Consultant, Interpharm Consultancy
Richard Dicicco

Richard Dicicco

Chairman, Harvest Moon Pharmaceuticals
Steinar Madsen

Steinar Madsen

Medical Director, Norwegian Medicines Agency

Alan Sheppard

Global Head Generics, Thought Leadership, IMS Health
Alan Sheppard

Albin (Jim) Nelson

Partner, Schwegman, Lundberg, Woessner IP, P.A.
Albin (Jim) Nelson

Alok Sharma

Principal Scientist & Head Analytical Development , Lupin Laboratories Ltd
Alok Sharma

Carsten Brockmeyer

CEO, Formycon AG
Carsten Brockmeyer

Catherine Akers

Regulatory Affairs Manager, Amgen Inc
Catherine Akers

Dominic Adair

Partner, Bristows
Dominic Adair

Erik A. Stene

Senior Advisor/MPhil Econ, Department for pharmacoeconomics/reimbursement/value assessment, Norwegian Medicines Agency
Erik A. Stene

Ineke Braat

CEO, PanGenerika
Ineke Braat

Liz Fuller

Partner, Bird & Bird
Liz Fuller

Michael Tovey

INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan
Michael Tovey

Michel Mikhail

Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Fresenius Kabi
Michel  Mikhail

Peter Wittner

Senior Consultant, Interpharm Consultancy
Peter Wittner

Rakesh Dixit

Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune (AstraZeneca Biologics)
Rakesh Dixit

Ranjith Gopinathan

Program Manager - Life Sciences, Healthcare Practice Europe, Frost & Sullivan
Ranjith  Gopinathan

Richard Dicicco

Chairman, Harvest Moon Pharmaceuticals
Richard Dicicco

Robin Chadwick

Partner, Schwegman, Lundberg, Woessner IP
Robin Chadwick

Samuel Woodley

U.S. Senior Patent Attorney, Biosimlars Business, Boehringer Ingelheim Pharma GmbH & Co. KG
Samuel Woodley

Sarah Faircliffe

Legal Director , Bird & Bird
Sarah Faircliffe

Steinar Madsen

Medical Director, Norwegian Medicines Agency
Steinar Madsen

Uwe Gudat

Head of Safety Biosimilars, Merck Switzerland Limited
Uwe Gudat

Victoria Fine

Managing Director , Psoriansense
Victoria Fine

Sponsors and Exhibitors

Official Media Partner

Supporters

Workshops

Biosimilars – A Regulatory Update
Workshop

Biosimilars – A Regulatory Update

Holiday Inn Regents Park
1st October 2014
London, United Kingdom

Biosimilars – ‘The Holy Grail?’
Workshop

Biosimilars – ‘The Holy Grail?’

Holiday Inn Regents Park
1st October 2014
London, United Kingdom

Biosimilars and Biobetter - 2014 Attendees

Download

Biosimilars and Biobetters - Speakers Interviews 2014

Download

Sponsorship Manual

Download

PAST CONFERENCE ATTENDEES (2011-2013) BY COMPANY AND COUNTRY

Download

Sponsors and Exhibitors


Europa Bioproducts Ltd

Sponsors and Exhibitors
http://www.europa-bioproducts.com

Europa Bioproducts is the exclusive distributors for ProZyme Inc., who manufactures a very comprehensive range of reagents used for glycan profiling and characterization of therapeutic monoclonal antibodies and proteins. The GlykoPrep rapid glycan preparation technology allows companies with no previous experience to perform glycan analysis in house. After collaboration with Agilent Technologies, GlykoPrep has been automated on the Agilent Bravo liquid handling platform. We now have customers performing high throughput glycan profiling for clone selection and culture media optimization with this platform. Europa/ProZyme is now offering analytical support services to their European customers. We offer screening services for 100’s of samples using UPLC or CE. We can perform orthogonal methods such as UPLC and CE. We can perform in depth characterisation of N-Glycans using UPLC/MS, exoglycosidases and also domain specific analysis of antibodies.


Schwegman, Lundberg & Woessner

Sponsors and Exhibitors
http://www.slwip.com/

Schwegman Lundberg & Woessner is a nationally recognized boutique IP firm focused on strategic patent procurement with over 140 patent practitioners that have robust backgrounds across a wide spectrum of technology areas. Schwegman's clients include multinational corporations, middle-market businesses, universities, as well as start-ups and individual inventors.

Media Partners


BiosimilarNews

Official Media Partner
http://www.Biosimilarnews.com

Biosimilarnews.com is a weblog to share the knowledge about biosimilars. We wanted to build up a detailed source for professionals and also for the public. Our only aim is to share our knowledge and also keep in touch with the professionals who are working in this specific area. Biosimilar News - We keep you up to date.

Media Partners


World Pharma Today

Supporters
http://www.worldpharmatoday.com



Biotechgate

Supporters
http://www.biotechgate.com/gate/v3/companies.php

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 38,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.


Pharma Marketing News

Supporters
http://www.news.pharma-mkting.com/

Pharma Marketing News is an independent monthly electronic newsletter focused on issues of importance to pharmaceutical marketing executives. It is a service of the Pharma Marketing Network -- The First Forum for Pharmaceutical Marketing Experts -- which brings together pharmaceutical marketing professionals from manufacturers, communications companies, and marketing service providers for wide ranging discussions and education on a multitude of current topics. Pharma Marketing Network & Pharma Marketing News provide executive-level content coupled with permission-based e-marketing opportunities.


Pharmaceutical International

Supporters
http://www.pharmaceutical-int.com

Pharmaceutical International is a total resource for buyers such as chemists, pharmacists, industrial pharmaceutical manufacturers, legislative bodies, hospitals, research laboratories and other people within the industry who have annual buying power of billions of pounds estimated to be in the region of £400 billion per year. Pharmaceutical International is a total resource enabling the user to find the latest exhibitions, events, suppliers, products and services servicing the entire industry today. Whether you are searching for a simple pill or a turnkey laboratory solution you should be able to find the answer on this comprehensive web platform.


Lab Bulletin

Supporters
http://www.labbulletin.com

Lab Bulletin is a free online resource for scientists and laboratory professionals where you can catch up on the latest news for laboratory products and services. You will find an extensive directory of laboratory suppliers and manufacturers enabling you to contact companies quickly and easily to request further information. Lab Bulletin also publishes four free monthly E-Newsletters keeping you up-to-date with all of the latest laboratory products and industry news directly to your inbox. We have dedicated E-Newsletters for Chromatography and Spectroscopy, Microscopy and Image Analysis, weekly Industry News updates and our monthly Lab Bulletin E-Newsletter sent out to over 29,000 readers worldwide. To request your free copy click here


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


Frost & Sullivan

Supporters
http://www.frost.com

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation


Thomson Reuters

Supporters
http://thomsonreuters.com/products_services/science/

Thomson Reuters is the leading source of intelligent information for professionals around the world. We provide essential information to keep you in touch with the rapidly-changing pharmaceutical and chemical markets, expert services to help you make informed, early decisions, and intuitive technology to manage and support your discovery and development activities. Our products give you the intelligence, tools and expertise to help you optimize your IP portfolio, monitor industry developments, identify licensing and partnering opportunities, deliver successful regulatory submissions, and support your scientific messaging, marketing, product positioning, and awareness campaigns.


Cutting Edge

Supporters
http://www.cuttingedgeinfo.com

Cutting Edge Information provides customized research and benchmarking reports to pharmaceutical, biotechnology and other life science companies. We provide off-the-shelf and customized research for key areas including medical affairs, clinical development, market access, regulatory affairs, marketing management, sales and HCP fair market value.


PharmCast

Supporters
http://www.PharmCast.com

www.PharmCast.com is the world leading website designed specifically for pharmaceutical, clinical and biotechnology professionals. www.PharmCast.com brings up-to-date information on pharmaceutical patents, FDA, news, jobs and Buyer's Guide to our visitors. It was created and is maintained by pharmaceutical and biotechnology professionals. Visit www.PharmCast.com and discover for yourself why it is so popular among professionals.


Biotechnology Europe

Supporters
http://www.biotechnology-europe.com

BIOTECHNOLOGY-EUROPE.com is provided by BIOTECHNOLOGY WORLD, facilitates the exchange of information by promoting research within biotech sector. These include all participants in the sector such as government bodies, researchers, consumers, biotechnology companies, journalists and venture capital companies, biotech nationals organizations. Links and collaborations with other industrial networks add up to the BIOTECHNOLOGY-EUROPE`s own extensive database.


Antibodies Online

Supporters
http://www.antibodies-online.com

antibodies-online.com facilitates researchers to find the appropriate antibodies for their respective research project. As an independent and multi-vendor marketplace for research antibodies and thanks to the cooperation with more than 130 different manufacturers, a large selection of Antibodies (over 700,000), ELISA Kits (over 130,000), Secondary Antibodies (17,000), Proteins (130,000), Peptides and Isotype Controls is available. By supporting the Independent Validation Initiative and the Resource Identification Initiative, antibodies-online.com also addresses the important topics of transparent product quality and scientific reproducibility. In addition scientists receive news and detailed information about the individual antibodies from databases such as the PubMed and others.


Technology Networks

Supporters
http://www.technologynetworks.com

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Mednous

Supporters
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


Bioportfolio Limited

Supporters
http://www.bioportfolio.com

BioPortfolio.com is a leading news, information and knowledge resource covering the global life science industries impacted by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to source core information on specific bio-related topics, to collate relevant data associated with each topic and to point the user to relevant knowledge resources


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


Select Science

Supporters
http://www.selectscience.net/

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


LabRoots

Supporters
http://www.labroots.com/

LabRoots is a free, social networking site that enables scientists, engineers, and other technical professionals to connect, collaborate with, and learn from each other. LabRoots fosters world-wide scientific communication and incorporates the newest social networking technologies. LabRoots allows scientists to connect with each other as they describe their research interests on a myriad of unique features and tools, discovering meaningful collaborations across geographic boundaries and fields of expertise.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


Drug Target Review

Supporters
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


Farmavita

Supporters
http://www.farmavita.net/

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.

Holiday Inn Regents Park

Carburton Street
London W1W 5EE
United Kingdom

Holiday Inn Regents Park

Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.